Short Interest in HLS Therapeutics Inc. (OTCMKTS:HLTRF) Decreases By 9.1%

HLS Therapeutics Inc. (OTCMKTS:HLTRF) saw a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 2,000 shares, a drop of 9.1% from the March 15th total of 2,200 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 20.0 days.

Wall Street Analyst Weigh In

Separately, Raymond James lowered their target price on HLS Therapeutics from $6.50 to $5.00 and set a “market perform” rating on the stock in a research note on Monday, March 18th.

HLS Therapeutics Price Performance

Shares of HLTRF remained flat at $3.85 during trading hours on Tuesday. The stock’s 50-day moving average is $3.24 and its 200-day moving average is $3.35. HLS Therapeutics has a 1-year low of $2.60 and a 1-year high of $4.95.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.